Masafumi Ikeda

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. doi request reprint A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis
    Masafumi Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 72:463-70. 2013
  2. doi request reprint Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, 277 8577, Japan
    J Vasc Interv Radiol 24:490-500. 2013
  3. doi request reprint Reactivation of hepatitis B virus in patients receiving chemotherapy
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, 277 8577, Japan
    Jpn J Clin Oncol 43:8-16. 2013
  4. doi request reprint A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Int J Radiat Oncol Biol Phys 85:163-9. 2013
  5. doi request reprint Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 38:675-82. 2008
  6. ncbi request reprint Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer
    Junji Furuse
    National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 36:552-6. 2006
  7. ncbi request reprint A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 69:421-7. 2005
  8. doi request reprint Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms
    Emiko Sugiyama
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Clin Pharmacokinet 49:549-58. 2010
  9. doi request reprint Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites
    Atsuko Soeda
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji Chuo ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 40:1184-8. 2010
  10. doi request reprint Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 69:957-64. 2012

Collaborators

Detail Information

Publications68

  1. doi request reprint A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis
    Masafumi Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Chemother Pharmacol 72:463-70. 2013
    ....
  2. doi request reprint Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, 277 8577, Japan
    J Vasc Interv Radiol 24:490-500. 2013
    ..To evaluate the safety and efficacy of transcatheter arterial chemoembolization used for the treatment of unresectable hepatocellular carcinoma (HCC) with an Asian cooperative prospective study between Japan and Korea...
  3. doi request reprint Reactivation of hepatitis B virus in patients receiving chemotherapy
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, 277 8577, Japan
    Jpn J Clin Oncol 43:8-16. 2013
    ..have not been fully clarified. A variety of well-designed prospective studies are currently under way in both Japan and abroad, and strong evidence of hepatitis B virus reactivation following chemotherapy is anticipated in the future...
  4. doi request reprint A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Int J Radiat Oncol Biol Phys 85:163-9. 2013
    ..The aim of this trial was to evaluate the efficacy and toxicity of S-1 and concurrent radiation therapy for locally advanced pancreatic cancer (PC)...
  5. doi request reprint Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 38:675-82. 2008
    ..The aim of this study was to identify factors that could be used to predict outcome and tumor response to systemic chemotherapy in patients with metastatic HCC...
  6. ncbi request reprint Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer
    Junji Furuse
    National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 36:552-6. 2006
    ..The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract cancer...
  7. ncbi request reprint A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 69:421-7. 2005
    ..The aim of this study was to determine the maximum-tolerated dose and dose-limiting toxicity (DLT) of combination therapy with gemcitabine and S-1 in patients with advanced pancreatic cancer...
  8. doi request reprint Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms
    Emiko Sugiyama
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Clin Pharmacokinet 49:549-58. 2010
    ..The aim of this study was to determine the factors, including genetic polymorphisms of CDA, DCK and solute carrier family 29A1 (SLC29A1 [hENT1]), that alter the pharmacokinetics of gemcitabine in Japanese cancer patients...
  9. doi request reprint Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites
    Atsuko Soeda
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji Chuo ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 40:1184-8. 2010
    ..Therefore, we need to monitor patients for late-onset, severe and long-lasting skin reactions at injection sites in Wilms tumor-1 cancer vaccine therapy, particularly for combination treatment with gemcitabine...
  10. doi request reprint Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 69:957-64. 2012
    ..We conducted the phase I/II of FDR-Gem and S-1 (FGS) in patients with Gem-refractory PC...
  11. doi request reprint A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 63:313-9. 2009
    ..5% in chemo-naïve patients with pancreatic cancer. This study evaluated the efficacy and toxicity of S-1 in patients with gemcitabine-refractory metastatic pancreatic cancer...
  12. ncbi request reprint Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 37:515-20. 2007
    ..The objectives of this study were to evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine and cisplatin in patients with metastatic pancreatic cancer...
  13. ncbi request reprint Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis
    Masafumi Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 72:188-93. 2007
    ..The objective of this study was to evaluate the antitumor, survival, and adverse effects of hepatic arterial infusion chemotherapy using epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis...
  14. ncbi request reprint Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC)
    Yoriko Takezako
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Hepatogastroenterology 55:1380-4. 2008
    ..To clarify the efficacy and toxicity of cisplatin, epirubicin, and continuous infusion of 5-FU (CEF therapy) in patients with advanced intrahepatic cholangiocellular carcinoma (ICC)...
  15. ncbi request reprint Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients
    Chigusa Morizane
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 68:432-7. 2005
    ..This study investigated the outcome and tolerability of this treatment in elderly patients...
  16. doi request reprint Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer
    Miho Kaida
    Department of Medical Oncology, National Cancer Research Center Hospital, Chuo Ku, Tokyo, Japan
    J Immunother 34:92-9. 2011
    ..Although objective clinical efficacy was not apparent, the safety of WT1 vaccine and GEM combination therapy was confirmed in this study...
  17. doi request reprint Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas
    Satoru Iwasa
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Jpn J Clin Oncol 40:313-8. 2010
    ..However, there were no prior reports limited to the hepatobiliary tract and pancreas as the primary sites...
  18. doi request reprint Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
    Satoru Iwasa
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 41:770-5. 2011
    ....
  19. doi request reprint A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Kohei Nakachi
    Division of Hepatobiliary, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
    Cancer Chemother Pharmacol 66:527-34. 2010
    ..The aim of this study was to investigate the feasibility and efficacy of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer...
  20. ncbi request reprint Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma
    Kazuaki Shimada
    Division of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo, Japan
    Ann Surg Oncol 14:2337-47. 2007
    ..In addition, selections of the most effective treatments for patients with recurrent HCC still remain controversial...
  21. ncbi request reprint [S-1 monotherapy for pancreatic cancer]
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Gan To Kagaku Ryoho 33:207-12. 2006
    ..S-1 is active and well tolerated in patients with metastatic pancreatic cancer. Randomized trials are warranted to determine the effectiveness of S-1 for the treatment of pancreatic cancer...
  22. doi request reprint Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases
    Eiichiro Suzuki
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Oncology 79:39-45. 2010
    ..The purpose of this study was to elucidate the treatment efficacy and safety of gemcitabine monotherapy, and to identify prognostic factors in patients with advanced biliary tract cancer receiving this therapy...
  23. ncbi request reprint Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 32:455-60. 2002
    ..This study investigated prognostic factors in patients with advanced hepatocellular carcinoma treated by transcatheter arterial embolization...
  24. doi request reprint Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy
    Tsutomu Tanaka
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 38:755-61. 2008
    ..The purpose of the retrospective analysis is to elucidate the treatment efficacy and toxicity as well as to identify prognostic factors in Japanese patients with advanced pancreatic cancer treated with gemcitabine...
  25. ncbi request reprint A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma
    Masafumi Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 35:439-43. 2005
    ..However, its activity in biliary tract carcinoma has not been fully evaluated. The aim of this study was to evaluate the antitumor activity and toxicity of UFT in chemotherapy-naive patients with advanced biliary tract carcinoma...
  26. ncbi request reprint [5 -fluoropyrimidines for treatment of biliary tract cancers]
    Chigusa Morizane
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital
    Nihon Rinsho 64:529-33. 2006
  27. doi request reprint Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study
    Hideki Ueno
    Taiho Pharmaceutical, Tokyo, Japan
    J Clin Oncol 31:1640-8. 2013
    ..The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority of gemcitabine plus S-1 compared with gemcitabine alone with respect to overall survival...
  28. ncbi request reprint Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 35:733-8. 2005
    ..The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m(2)/min) on a weekly schedule to Japanese patients with unresectable advanced pancreatic cancer...
  29. ncbi request reprint [Non-surgical treatment for pancreatic cancer]
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital
    Nihon Shokakibyo Gakkai Zasshi 103:391-7. 2006
  30. doi request reprint Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
    Kenji Hashimoto
    National Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division, Tokyo, Japan
    Oncology 77:217-23. 2009
    ..Whether recurrence after surgery and primary metastatic pancreatic cancer should be included in the same category when conducting gemcitabine-based clinical trials remains controversial...
  31. doi request reprint Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma
    Chigusa Morizane
    National Cancer Center Hospital, Tokyo, Japan
    Pancreas 40:415-21. 2011
    ..To identify prognostic factors in patients with metastatic pancreatic adenocarcinoma...
  32. doi request reprint Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent
    Yoshitaka Seki
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Jpn J Clin Oncol 39:751-5. 2009
    ..Prospective clinical trials are necessary to confirm the effectiveness of fluoropyrimidine for the treatment of pancreatic ACC...
  33. ncbi request reprint A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer 103:756-62. 2005
    ....
  34. ncbi request reprint [Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer]
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital
    Gan To Kagaku Ryoho 33:1515-9. 2006
    ..S-1 showed a promising antitumor effect and tolerability in patients with metastatic pancreatic cancer, and it was also considered to be beneficial for patients in terms of convenience of administration, that is, by the oral route...
  35. ncbi request reprint Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK)
    Su Ryang Kim
    Project Team for Pharmacogenetics, National Institute of Health Sciences, Tokyo, Japan
    Drug Metab Pharmacokinet 23:379-84. 2008
    ..Our findings suggest considerable ethnic differences in genetic variations of DCK and provide fundamental and useful information for genotyping DCK in the Japanese and probably other Asian populations...
  36. doi request reprint Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy
    Tomoko Katsui Taniyama
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tsukiji, Chuo Ku, Tokyo, Japan
    Pancreatology 12:428-33. 2012
    ..A global consensus on how to treat recurrent pancreatic cancer after adjuvant chemotherapy with gemcitabine (ADJ-GEM) does not exist...
  37. pmc A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
    Eiichiro Suzuki
    Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, 6 20 2, Shinkawa, Mitaka, Tokyo 181 8611, Japan
    Cancer Chemother Pharmacol 71:1141-6. 2013
    ..The present study was conducted to evaluate the efficacy and safety of S-1 in patients with GEM-refractory BTC...
  38. ncbi request reprint An early phase II study of S-1 in patients with metastatic pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, Japan
    Oncology 68:171-8. 2005
    ..The aim of this study was to evaluate the efficacy and toxicity of S-1 in patients with metastatic pancreatic cancer...
  39. ncbi request reprint Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer
    Hideki Ueno
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Oncology 67:215-21. 2004
    ..This study investigated the maximum-tolerated dose of hyperfractionated radiation therapy with protracted 5-fluorouracil (5-FU) infusion in patients with locally advanced, unresectable pancreatic cancer...
  40. ncbi request reprint Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer
    Yoshinori Ito
    Radiation Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Anticancer Res 26:3755-9. 2006
    ..This study evaluated the acute intestinal toxicity in relation to the volume of irradiated small bowel and other factors using dosimetric analyses in pancreatic cancer patients treated with gemcitabine-based chemoradiotherapy...
  41. ncbi request reprint A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization
    Tsutomu Tanaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Cancer Chemother Pharmacol 61:683-8. 2008
    ..The aim of this study was to evaluate the antitumor activity and toxicity of transcatheter arterial infusion chemotherapy using an epirubicin-Lipiodol emulsion in patients with TAE-refractory HCC...
  42. ncbi request reprint [Chemotherapy]
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Gan To Kagaku Ryoho 37:408-12. 2010
    ..After the introduction of sorafenib, chemotherapy for advanced hepatocellular carcinoma has been changing remarkably, and further improvements of chemotherapy for hepatocellular carcinoma are expected...
  43. ncbi request reprint [Chemotherapy for hepatocellular carcinoma]
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Gan To Kagaku Ryoho 31:2122-8. 2004
    ..No agent has reproducibly documented a high response rate, and few chemotherapeutic regimens show meaningful impact on patient survival. Numerous clinical trials have been conducted to establish effective treatment for patients with HCC...
  44. ncbi request reprint [Two cases of advanced extrahepatic bile duct cancer successfully treated by S-1 monotherapy]
    Hideki Ueno
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital
    Gan To Kagaku Ryoho 34:1311-4. 2007
    ..0%. In this article,we report two patients with advanced extrahepatic bile duct cancer enrolled in the study who showed a partial response to S-1 monotherapy...
  45. doi request reprint Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas
    Taiga Otsuka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
    Pancreas 42:889-92. 2013
    ....
  46. ncbi request reprint FP therapy for controlling malignant ascites in advanced pancreatic cancer patients
    Kan Yonemori
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Hepatogastroenterology 54:2383-6. 2007
    ..We conducted a retrospective analysis to evaluate the efficacy of 5-fluorouracil (5-FU) plus cisplatin (FP therapy) for controlling malignant ascites in patients with advanced pancreatic cancer...
  47. ncbi request reprint Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma
    Koichi Tokuuye
    Radiation Oncology Division, The National Cancer Center Hospital, Tokyo, Japan
    Radiother Oncol 67:327-30. 2003
    ..To evaluate the effectiveness of small-field radiotherapy in combination with concomitant 5-fluorouracil (5FU) or cisplatin for locally advanced pancreatic carcinoma...
  48. ncbi request reprint Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 62:223-7. 2002
    ..However, its activity in pancreatic cancer has not been fully evaluated. The aim of the present study was to evaluate the anti-tumor activity and toxicity of UFT in patients with metastatic pancreatic cancer...
  49. ncbi request reprint Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 62:228-33. 2002
    ..Grade 3 and 4 non-hematological toxicity (liver dysfunction) occurred in 17 (34%) and 7 patients (14%), respectively. TAE using SMANCS, which was well tolerated, may be an effective treatment for advanced HCC...
  50. doi request reprint Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma
    Mitsuhiko Kawashima
    Division of Particle Therapy and Radiation Oncology, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Int J Radiat Oncol Biol Phys 79:1479-86. 2011
    ..To evaluate the safety and efficacy of radiotherapy using proton beam (PRT) for unresectable hepatocellular carcinoma...
  51. doi request reprint Liver cryptococcosis manifesting as obstructive jaundice in a young immunocompetent man: report of a case
    Satoshi Nara
    Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Surg Today 38:271-4. 2008
    ..Unnecessary surgical intervention was avoided by an early and accurate diagnosis and effective antifungal therapy. The bile culture was the key to the definitive diagnosis in this case...
  52. doi request reprint Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 103:1524-30. 2012
    ..5%. In conclusion, the recommended dose of TAC-101 for patients with HCC is 20 mg/day. TAC-101 had an acceptable toxicity profile, warranting further evaluation in clinical trials...
  53. doi request reprint Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment
    Shinichiro Takahashi
    Department of Hepatobiliary Pancreatic Surgery, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
    J Hepatobiliary Pancreat Sci 18:567-74. 2011
    ..However, few reports are available on differences in tumor characteristics and prognoses among resectable pancreatic cancer (PC), BRPC, and unresectable PC...
  54. ncbi request reprint Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin
    Kan Yonemori
    Division of Hepatobiliary and Pancreatic Oncology and Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Clin Cancer Res 11:2620-4. 2005
    ....
  55. doi request reprint Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
    Shunsuke Kondo
    Department of Medical Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 18:207-13. 2013
    ..We evaluated c-Met protein expression and its gene amplification in order to assess whether they were related to tumor recurrence and survival rates among patients who had undergone tumor resection...
  56. ncbi request reprint Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection
    Hitoshi Kuriyama
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 17:1205-10. 2002
    ..However, only a few extensive investigations have been conducted regarding the prognostic factors for HCC patients treated with PEI...
  57. doi request reprint His595Tyr polymorphism in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk
    Shumpei Ohnami
    Genetics Division, National Cancer Center Research Institute, Tokyo, Japan
    Gastroenterology 135:477-88. 2008
    ..This study attempts to elucidate a part of the genetic predisposition to the sporadic invasive ductal adenocarcinoma of the pancreas focusing on the genes implicated in the gene-environment interactions in carcinogenesis...
  58. doi request reprint Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report
    Yusuke Nakayama
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Chemotherapy 59:74-8. 2013
    ..Physicians treating with everolimus should monitor patients closely for ILD and should apply appropriate management strategies to optimize the possibility of maintaining everolimus therapy...
  59. doi request reprint Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer
    Atsuko Soeda
    Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Jpn J Clin Oncol 39:797-806. 2009
    ..This study was designed to evaluate the immunological reaction by gemcitabine for future clinical trial of combination therapy with gemcitabine and cancer vaccines...
  60. doi request reprint Ultrasound-guided percutaneous pancreatic tumor biopsy in pancreatic cancer: a comparison with metastatic liver tumor biopsy, including sensitivity, specificity, and complications
    Junichi Matsubara
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Tokyo, 104 0045, Japan
    J Gastroenterol 43:225-32. 2008
    ....
  61. doi request reprint Impaired mental health among the bereaved spouses of cancer patients
    Mariko Asai
    Psycho Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan ac jp
    Psychooncology 22:995-1001. 2013
    ..The purpose of this study was to identify the prevalence of impaired mental health among the bereaved spouses over several years and explore the indicators for early detection of high-risk spouses during end-of life (EOL) care...
  62. doi request reprint Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805)
    Chigusa Morizane
    Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 104:1211-6. 2013
    ..This study was registered at the UMIN Clinical Trials Registry as UMIN 000001685 (http://www.umin.ac.jp/ctr/index.htm)...
  63. ncbi request reprint [Palliative therapy in patients with biliary tract cancer]
    Masafumi Ikeda
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital
    Nihon Rinsho 64:565-7. 2006
  64. ncbi request reprint Spontaneous regression of hepatocellular carcinoma
    Shunsuke Kondo
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Int J Clin Oncol 11:407-11. 2006
    ..Another showed spontaneous regression after taking several complementary and alternative medicines. However, the mechanisms underlying this intriguing phenomenon remain unknown...
  65. ncbi request reprint Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features
    Takuji Okusaka
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
    Cancer 95:1931-7. 2002
    ..It is not rare to find satellite lesions in patients with small hepatocellular carcinoma (HCC). The purpose of this study was to elucidate the factors associated with satellite lesions in these patients...
  66. doi request reprint Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer
    Akira Imoto
    Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Int J Cancer 131:2795-807. 2012
    ..These data provide the first evidence that N-inv induces cachexia via astrocytic activation of neural route in pancreatic cancer...
  67. doi request reprint Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333
    Takuji Okusaka
    National Cancer Center Hospital, Tokyo National Cancer Center East Hospital, Kashiwa City, Chiba, Japan
    Hepatol Res 41:542-52. 2011
    ..Conclusion:  Hypertension was noted as a DLT at the dose level of 900 mg/day, and this dose was considered to be inappropriate. The recommended dose for the phase II/III clinical trial is thought to be 300 mg/day and 600 mg/day...
  68. doi request reprint Psychological states and coping strategies after bereavement among spouses of cancer patients: a quantitative study in Japan
    Mariko Asai
    Psycho Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Support Care Cancer 20:3189-203. 2012
    ....